Adoptive transfer of T-cells engineered to express chimeric immunoreceptors is an effective strategy to treat hematological cancers, however, such therapy for solid cancers such as ovarian cancer remains challenging because a safe and effective immunotherapeutic target has not yet been identified. Here, we constructed and evaluated a novel redirected T-cell-based immunotherapy targeting human folliclestimulating hormone receptor (FSHR), a highly conserved molecule in vertebrate animals with expression limited to gonadal tissues, ovarian cancer and cancer-associated vasculature. Receptor ligand-based anti-FSHR immunoreceptors were constructed that contained small binding fragments from the ligand for FSHR, follicle stimulating hormone (FSH), fused to T-cell transmembrane and T-cell signaling domains. 
Introduction
The follicle-stimulating hormone receptor (FSHR) is a G-protein-coupled receptor that is primarily expressed in the granulosa cells of the ovary and the Sertoli cells of the testis of adults (1, 2) .
Although the role of FSHR expression in the development and progression of ovarian cancer is not fully understood, one hypothesis currently being tested is that gonadotrophin signals, including those transmitted through FSHR, may be involved in the transformation and progression of normal ovarian surface epithelium (OSE) to neoplastic OSE. Indeed, ovarian cancer is more common in conditions where gonadotropin levels are elevated, such as in post-menopausal women (3) . FSHR mRNA can be detected in ovarian cancer (4) , although protein detection by IHC has been challenging and requires further investigation. In vitro results from overexpressing cell lines suggest that the protein may play a role as a stimulator of cancer cell proliferation (5) , and treatment of some ovarian cancer cells with FSH, the ligand for FSHR, can result in growth stimulation in a dose-and time-dependent manner in vitro (6) , which suggests that FSHR-targeted therapy could be effective in ovarian cancer. Furthermore, recent biodistribution studies from Radu and colleagues show ubiquitous ectopic expression of FSHR in the tumor-associated blood vessels of various tumor types, including prostate adenocarcinoma, urothelial carcinoma, renal cell carcinoma and ovarian cancer, without detectable expression in surrounding healthy vasculature (7, 8) , although this finding has yet to be confirmed by others. The biological significance of its expression in tumor blood vessels remains unknown, but FSHR expression level correlates with the response to anti-angiogenic therapies and suggests that anti-FSHR therapy could be utilized broadly as a tumor vasculature disruption agent across solid malignancies. Thus, FSHR expression by both ovarian cancer cells and its tumor-associated vasculature (4,9) may provide a unique opportunity to deliver synergistic effects from a single, anti-FSHR therapy, thus making FSHR targeting particularly attractive in ovarian cancer.
T-cell targeting of antigens on the cancer cell surface can now be achieved through the genetic modification of primary T-cells to express a chimeric antigen receptor (CAR). Adoptive immunotherapy utilizing CAR T-cells specific for CD19 has been shown to induce durable remissions in hematological malignancies (10) , however, targeting of solid tumors has not yet achieved parallel success. Multiple factors may limit the efficacy and safety of this form of therapy in solid tumors, one of which being the risk associated with on-target, off-tumor toxicity. For example, CD19 CAR therapy induces profound B cell aplasia through coordinate elimination of healthy and malignant CD19+ B lymphocytes (10) , and transfer of ERBB2 CAR T-cells following lymphodepleting chemotherapy was associated with rapidonset respiratory arrest and death presumably via cytokine release by CAR T-cells triggered by the recognition of low levels of ERBB2 on lung epithelial cells (11) . The potential for on-target, off-tumor toxicity from CAR T-cell therapy has limited more widespread translation of this promising therapy to other malignancies. Still, the targeting of bona fide cancer/testis antigens, such as NY-ESO-1, with expression restricted to the ovary, male germ cells in the testis, and malignant cells but not somatic tissue, has paved the path for safe and effective gene-modified T-cell therapy (12) . In the absence of tumorrestricted antigens, other antigens that are expressed by tumor cells and cells of healthy organs with nonessential function for patient survival, such as reproductive organs, may be attractive targets for CARbased immunotherapy. FSHR is a member of this class of antigens. The restricted expression pattern of abundant FSHR in ovarian cancer (2, 4, 13) , tumor vessels (14, 15) and gonadal tissues (1), relative to that found in adult somatic tissues (16) , lowers the risk for on-target, off-tumor toxicity and makes FSHR an appealing target for T-cell-based immunotherapy.
In this study, we developed a strategy for the treatment of human ovarian cancer via the redirection of primary human T-cells against FSHR and validated for the first time the suitability of FSHR as a target of T-cell-based immunotherapy. Anti-FSHR immunoreceptors (IRs), specific for human and mouse FSHR, were created utilizing peptides derived from the natural FSHR ligand, FSH, for redirected T cell activity. Herein, we report the results of in vitro testing of FSHR-redirected T-cells for recognition and reactivity against human FSHR-expressing ovarian cancer cells, and the in vivo efficacy of anti-FSHR-IR T-cell therapy in a xenograft model of human ovarian cancer. This study serves as a foundation for future development of FSHR-targeted immunotherapies.
Materials and Methods

Anti-FSHR immunoreceptor (FSHR-IR) construction
Segments of FSH peptides including flanked 3'-Bam-H1, 5'-Nhe-1 restriction sites were synthesized.
DNA products were digested with Bam-HI and Nhe-I enzymes and ligated into pELNS, a third generation self-inactivating-lentiviral expression vector, containing human CD8alpha-hinge and transmembrane region fused to CD3z or CD28-CD3z signaling endodomains, under an EF-1α promoter. Resulting constructs were designated anti-FSHR IR-z and anti-FSHR-28z, respectively.
Recombinant lentivirus production
High-titer replication-defective lentiviral vectors were produced and concentrated as described (17) . 
Lymphocytes
Primary human CD4+ and CD8+ T-cells isolated from healthy volunteer donors were purchased from the Human Immunology Core at University of Pennsylvania, activated and transduced with lentiviral vectors as described (18).
Cell lines
The immortalized normal fetal renal 293T cell line and human cell lines used in immune based assays including CaOV3, CaOV434, SKOV3 and OVCAR3 were purchased from and maintained according to ATCC. The murine mesothelioma cell line, AE17, and murine ovarian cancer cell line, ID8, were provided by Steven M. Albelda and George Coukos at the University of Pennsylvania, respectively. Cells were transfected with firefly luciferase as described (18).
Flow cytometric analysis
APC-Cy7 Mouse Anti-Human-CD3; FITC-anti-human-CD4; APC-anti-human-CD8; PE-human-CD45; APC-human-CD69 antibodies were purchased from (Biolegend). FSHR expression was detected using clone6266717 ( R&D Systems). T-cell transduction was measured by GFP transgene expression. 7AAD (Biolegend) was used to assess viability. For in vivo T-cell quantification, 50μL blood was obtained from mice via retro-orbital bleeding and labeled for human CD45, CD3, and CD8. Cell numbers were quantified using BD TruCount tubes per manufacturer's instructions. Flow cytometry data were analyzed using FlowJo software.
FSHR -PCR
Total RNA was extracted from 5x106 viable tumor cells using RNeasy Mini kit (Qiagen). RNA quantity and quality were verified using a NanoDrop 2000 spectrophotometer (Thermo). cDNA was generated from 1μg total RNA using the High-Capacity-RNA-to-cDNA kit (Applied Biosystems). The human-FSHR was PCR-amplified using the following primers: 5′-CTCACCAAGCTTCGAGTCATCCAA-3′ and 5′-GCTCATCTAGTTGGGTTCCATT-3′ (GeneID: 2492), mouse-FSHR 5′-GGGATCTGGATGTCATCACT-3′ and 5′-GGAGAACACATCTGCCTCTA-3′ (GeneID: 14309).
Cytokine release assays and intracellular cytokine staining (CBA)
Cytokine release assays were performed by co-culture of 1x10 5 
FSHR-IR T-cells with FSHR-expressing
CaOV3 and FSHR-negative 293T cells, or mouse FSHR-expressing ID8, as described previously (18).
After 16h, co-culture supernatants were assayed for presence of cytokines using an ELISA Kit Bioluminescent Reporter Gene Assay (Applied Biosystems) was used to measure residual luciferase activity from remaining targets, and lysis was calculated as follows: Percent Lysis = 100-[(average signal from T-cell-treated wells)/(average signal from untreated target wells) x100].
Xenograft model of OvCa
NOD/SCID/γ-chain−/− (NSG) mice were bred, treated, and maintained under pathogen-free conditions in-house under University of Pennsylvania IACUC-approved protocols. Six to twelve week old female mice were purchased from the University of Pennsylvania Stem Cell and Xenograft Core and 5x10 6 CaOV3-fLuc tumor cells were inoculated subcutaneously (5 mice/group). Twenty and 25 days later, mice were injected intravenously with 6x10 6 T-cells. Tumor growth was assessed by weekly caliper measurements. Tumor volume was calculated using the following formula: V=1/2(length×width 2 ), where length is greatest longitudinal diameter and width is greatest transverse diameter.
Statistical analysis
Student's t-test was used to evaluate differences in T-cells specific cytolysis and cytokine secretion.
GraphPad Prism 4.0 (GraphPad Software) was used for the statistical calculations. P<0.05 was considered significant. 
Results/Discussion
Generation of the anti-FSHR immunoreceptors
Chimeric immunoreceptor was constructed for the redirection of primary human T-cells against FSHRexpressing targets. Follicle-stimulating hormone (FSH), the natural ligand for FSHR, was selected as the binding moiety for the immunoreceptor. FSH is a heterodimeric glycoprotein gonadotropin, consisting of α and β subunits, and several peptides derived from either the FSH beta subunit alone or mixed β/α subunits are reported to specifically bind to FSHR, as high affinity FSHR agonists or antagonists (18).
Based on their predicted binding affinity for FSHR, we selected multiple anti-FSHR peptides for the construction of a panel of chimeric immunoreceptors shown in Table 1 
FSHR-redirected T-cells exhibit antigen-specific reactivity against tumor targets.
First, established human ovarian cancer cell lines were characterized for cell surface FSHR expression. IFNg and TNF-alpha production was significantly lower in response to ID8 cells, with almost negligible levels of IL2 detected. This may be due to a lower affinity of the anti-FSHR-IRs for mouse FSHR than human FSHR protein, or antigen density, as our anti-human antibody was unable to detect murine FSHR.
Anti-FSHR-IR T cells did however specifically upregulate cell surface expression of CD69, an activation marker, when cocultured with FSHR + CaOV3 or ID8 cells. FSHR-deficient cell lines did not impact CD69 level, confirming antigen specific reactivity against both mouse and human FSHR + cell lines.
Control GFP and anti-FSHR 51-65β-28z T-cells did not respond to either cell line ( Figure 3B) .
Collectively, these data indicate that anti-FSHR-IRs can confer T-cells with the capacity to specifically recognize human and mouse FSHR protein expressed on the tumor cell surface.
Anti-FSHR-IR T-cells mediate antigen-specific tumor cell killing in vitro.
In order to evaluate the lytic proficiency of anti-FSHR-IR T-cells, we first engineered FHSR-positive and 
FSHR-redirected primary human T-cells suppress tumor growth in vivo.
To 
